Institutional members access full text with Ovid®

Share this article on:

Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial

Schmieder, Roland Ea; Philipp, Thomasb; Guerediaga, Javierc; Gorostidi, Manuelc; Bush, Christopherd; Keefe, Deborah Ld

doi: 10.1097/HJH.0b013e32832be593
Original papers: Therapeutic aspects

Objectives To compare the long-term efficacy, safety and tolerability of the direct renin inhibitor aliskiren against the diuretic hydrochlorothiazide (HCTZ) in obese patients with hypertension.

Methods A post hoc analysis of 396 obese patients (body mass index ≥30 kg/m2) in a 52-week study in 1124 patients with hypertension was performed. Patients were randomized to receive aliskiren 150 mg or HCTZ 12.5 mg for 3 weeks, or placebo for 6 weeks. At week 3, active treatment doses were doubled. Patients receiving placebo were randomized to aliskiren 300 mg or HCTZ 25 mg at week 6. Add-on amlodipine 5–10 mg was permitted from week 12 to achieve blood pressure (BP) control (<140/90 mmHg).

Results In the subgroup of obese patients, aliskiren monotherapy provided significantly greater BP reductions than HCTZ at week 12 endpoint (−16.7/−12.3 vs. −12.2/−9.1 mmHg, P ≤ 0.001). Reductions were also greater with aliskiren-based therapy than HCTZ-based therapy at week 52 endpoint (−19.9/−15.5 vs. −17.5/−13.3 mmHg; P = 0.138 for systolic BP and P = 0.007 for diastolic BP). Mean BP reductions from baseline with aliskiren-based therapy were similar in obese and nonobese patients. By contrast, HCTZ-based therapy provided significantly smaller mean reductions in BP from baseline in obese patients vs. nonobese patients (P < 0.05). Aliskiren-based therapy was generally well tolerated in obese patients, and was associated with a significantly lower incidence of hypokalemia (1.0 vs. 14.0%, P < 0.0001) than HCTZ-based therapy.

Conclusion Aliskiren-based therapy provided superior BP reductions to HCTZ-based therapy with good tolerability in obese patients with hypertension.

aDepartment of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany

bDepartment of Nephrology, University Hospital, Essen, Germany

cDepartment of Nephrology, Hospital San Agustin, Avilés, Spain

dNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Received 19 December, 2008

Revised 5 March, 2009

Accepted 20 March, 2009

Correspondence to Professor Roland E. Schmieder, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Krankenhausstrasse 12, 91054 Erlangen, Germany Tel: +49 9131 853 6245; fax: +49 9131 853 9209; e-mail: Roland.Schmieder@rzmail.uni-erlangen.de

© 2009 Lippincott Williams & Wilkins, Inc.